An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01012622 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride

Sponsor

Janssen Korea, Ltd., Korea